January 2013 FDA Recall Drug by Gilead Sciences, Inc.
D-324-2013 - Presence of Particulate Matter

This Class I drug recall was voluntarily initiated by Gilead Sciences, Inc. on January 31, 2013 for the product Drug. The FDA reported the reason for recall as presence of particulate matter. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-324-2013

Reason for Recall
Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).
Initiated
01-31-2013
Reported
05-22-2013
Quantity
3,181 vials

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Gilead Sciences, Inc.
Nationwide in USA, Canada, and UK (Gilead facility in Cork Ireland). Cork facility distributed to Germany/Austria, Italy and Spain.
Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.

Batch or Lot Expiration Information

Lot# : B120217A, Exp 05/15 - US Distribution